TRIM63: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: TRIM63

NCBI ID: G84676

TRIM63

TRIM63: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

TRIM63 (MURF2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and biology have made it an attractive target for researchers to study and develop new treatments.

TRIM63 is a small RNA molecule that consists of 21 amino acid residues. It is characterized by a unique structure that consists of a stem-loop and a 5'-end cap. The stem-loop is a common structural element that is found in all RNA molecules, while the 5'-end cap is a terminal structure that is also found in all RNA molecules.

One of the unique features of TRIM63 is its ability to self-cleavage, which means that it can break down into smaller pieces on its own. This self-cleavage mechanism allows TRIM63 to interact with various proteins and create a complex structure that can be targeted by these proteins.

TRIM63 has been shown to play a role in various cellular processes, including cell growth, differentiation, and RNA homeostasis. It has been shown to regulate gene expression, promote protein translation, and interact with various RNA-protein interactions.

One of the most promising aspects of TRIM63 is its potential as a drug target. Its unique structure and self-cleavage mechanism make it an attractive target for small molecule inhibitors. Researchers have identified several small molecules that can interact with TRIM63 and have shown that these inhibitors can reduce the levels of TRIM63 in various cell types.

TRIM63 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be altered in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that TRIM63 may be a useful biomarker for these diseases and could be used to develop new treatments.

In conclusion, TRIM63 is a non-coding RNA molecule that has unique structure and biology. Its ability to self-cleavage and its role in various cellular processes make it an attractive target for small molecule inhibitors. Its potential as a drug target and biomarker make it an exciting area of 鈥嬧?媟esearch for the development of new treatments for various diseases.

Protein Name: Tripartite Motif Containing 63

Functions: E3 ubiquitin ligase. Mediates the ubiquitination and subsequent proteasomal degradation of CKM, GMEB1 and HIBADH. Regulates the proteasomal degradation of muscle proteins under amino acid starvation, where muscle protein is catabolized to provide other organs with amino acids. Inhibits de novo skeletal muscle protein synthesis under amino acid starvation. Regulates proteasomal degradation of cardiac troponin I/TNNI3 and probably of other sarcomeric-associated proteins. May play a role in striated muscle atrophy and hypertrophy by regulating an anti-hypertrophic PKC-mediated signaling pathway. May regulate the organization of myofibrils through TTN in muscle cells

The "TRIM63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets